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Abstract
Background: Dystroglycanopathy (α-DG) is a relatively common, clinically and genetically heterogeneous category
of congenital forms of muscular dystrophy (CMD) and limb-girdle muscular dystrophy (LGMD) associated with
hypoglycosylated α-dystroglycan. To date, mutations in at least 19 genes have been associated with α-DG.
One of them, GMPPB, encoding the guanosine-diphosphate-mannose (GDP-mannose) pyrophosphorylase B
protein, has recently been associated with a wide clinical spectrum ranging from severe Walker-Warburg syndrome to
pseudo-metabolic myopathy and even congenital myasthenic syndromes.
We re-sequenced the full set of known disease genes in 73 Italian patients with evidence of either reduced or nearly
absent α-dystroglycan to assess genotype-phenotype correlations in this cohort. We used innovative bioinformatic
tools to calculate the effects of all described GMPPB mutations on protein function and attempted to correlate them
with phenotypic expressions.
Results: We identified 13 additional cases from 12 families and defined seven novel mutations. Patients displayed
variable phenotypes including less typical pictures, ranging from asymptomatic hyperCKemia, to arthrogryposis and
congenital clubfoot at birth, and also showed neurodevelopmental comorbidities, such as seizures and ataxic gait, as
well as autism-spectrum disorder, which is seldom described in clinical reports of dystroglycanopathies. We also
demonstrated that few mutations recur in the Italian GMPPB-mutated population and that alterations of protein
stability are the main effects of GMPPB missense variants.
Conclusion: This work adds to the data on genotype-phenotype correlations in α-DG and offers new bionformatic
tools to provide the conceptual framework needed to understand the complexity of these disorders.
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Background
Muscular dystrophies with evidence of reduced glycosyl-
ation of the transmembrane glycoprotein α-dystroglycan
on skeletal muscle biopsy [1] are collectively termed
α-dystroglycanopathy (α-DG) [2–4], and they constitute
a clinically and genetically heterogeneous group of auto-
somal recessive muscular dystrophies with variable
neurological and ophthalmic involvement.
The phenotypic severity of α-DG patients is extremely
variable. At the most severe end of the clinical spectrum
we find Walker-Warburg syndrome (WWS), muscle-
eye-brain disease and Fukuyama congenital muscular
dystrophy. These conditions are characterized by con-
genital muscular dystrophy (CMD) and severe structural
brain and eye abnormalities, leading to early infantile
death in WWS [5]. Conversely, individuals at the
mildest end of the clinical spectrum may present,
sometimes in adulthood, with limb-girdle muscular
dystrophy (LGMD), and without associated brain or
eye involvement [6].
Mutations in six genes (POMT1, POMT2, POGnT1,
FKRP, FKTN, and LARGE) are by far the most common
in large Italian and UK cohorts ascertained by low
skeletal muscle expression of α-dystroglycan [7, 8],
but they account for only about 50% of cases,
leaving the rest without a molecular diagnosis. The
advent of next-generation sequencing (NGS) method-
ologies has rapidly expanded the number of α-DG-
related genes and subsequently resulted in an expansion
of the clinical spectrum observed in affected children
and adults [9, 10].
To date, mutations in 19 genes coding for dystroglycan
itself or more frequently, for glycosyltransferases and
accessory proteins involved in the post-translational
modification of α-dystroglycan, are documented to be
responsible for the different forms of α-DG. One of them,
GMPPB, coding for the guanosine-diphosphate-mannose
(GDP-mannose) pyrophosphorylase B protein, seems to
be particularly frequent and is associated with a wide
spectrum of muscle weakness, ranging from WWS to a
mild form of adult-onset LGMD overlapping with differ-
ent congenital myasthenic syndromes (CMSs) [11–13].
More recently pseudo-metabolic features have been de-
scribed in few patients [14, 15]. Overall, about 81
GMPPB-mutated patients have been described worldwide:
56 with LGMD or overlapping LGMD-CMS phenotypes
and the rest presenting features of CMD. To assess the
relative frequency of GMPPB variants and contribute to
the definition of the associated clinical manifestations, we
systematically screened a large Italian population of α-DG
patients for mutations. We used new bioinformatics tools
to assess how mutations found in this study may affect
protein function. We then combined the data from
available families to determine mutation frequencies
in relation to clinical severity, and thus establish more
precise genotype-phenotype correlations.
Methods
This study was approved by the ethics committees of
our institutions. The patients were recruited after writ-
ten informed consent that had been obtained in accord-
ance with national regulations.
All the cases are part of a multicenter study that aims
to improve molecular characterization of presently un-
defined forms of CMD associated with defective glyco-
sylation of α-dystroglycan. For the present work, we
collected all genetically undefined patients with low
α-dystroglycan levels currently followed at any of the
tertiary care centers for pediatric and adult neuromuscu-
lar disorders belonging to the Italian CMD network.
Cases with milder phenotypes, and a possible diagnosis
of LGMD or LGMD-CMS, were also investigated.
We selected, from the overall network population, 105
patients with muscle biopsy-confirmed low α-dystroglycan
expression. Prior to our molecular investigations, two ex-
pert co-authors (C.F., A.R.) blindly reviewed these pa-
tients’ histological and immunohistochemical features. On
the basis of their findings, 32 patients, with a reduction of
α-dystroglycan likely unrelated to glycosylation defects, or
no reduction at all, were excluded. Thus, our study in-
cluded 73 patients fully meeting the diagnostic criteria for
dystroglycanopathy described elsewhere [9].
In this work, past medical history and clinical informa-
tion, as well as neurophysiological, brain MRI and myoi-
maging (available only in two patients) are described for
the 13 patients in whom we identified bi-allelic muta-
tions in GMPPB. Patients who showed a significant
delay in motor abilities and late acquisition of walking
(> 24 months) were classified as affected by CMD,
whereas those in whom overt clinical manifestations ap-
peared later, as described elsewhere [16], were deemed to
present with LGMD. Clinical subcategories of CMD were
defined as others have done [17]. Whenever possible pa-
tients have since been reassessed and submitted to a de-
tailed clinical re-examination.
Molecular genetic analyses were carried out in all 73
patients and, when available, in their parents and sib-
lings. Genomic DNA was purified from whole blood
using standard methodologies and the coding regions of
93 genes linked to CMD, LGMD or related diseases were
investigated in a single tube using Dystroplex, an ex-
tended NGS testing panel covering at high depth the
tested genes and described elsewhere [15, 18]. In all the
cases, sequencing was performed with Illumina technology
and standard bioinformatics pipelines were applied for qual-
ity control, mapping, variant calling and annotation. Publicly
available databases (HGMD: http://www.hgmd.cf.ac.uk/ac/
index.php; LOVD: http://www.dmd.nl/; 1000G database:
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http://www.1000genomes.org/; dbSNP database: http://
www.ncbi.nlm.nih.gov/SNP/; Sequencing Initiative Suomi
(SISu): www.sisuproject.fi; gnomAD; http://gnomad.broad
institute.org/; ExAC: http://exac.broadinstitute.org/ and
EVS: http://evs.gs.washington.edu/EVS/) (last access
December 2017) were interrogated to identify previously re-
ported variants and also to determine the frequency of the
novel variants observed. The pathogenicity assessment of
the target variant was performed according to the guidelines
published by the American College of Medical Genetics for
the interpretation of sequence variants [19]. Standard in
silico tools (Polyphen: http://genetics.bwh.harvard.edu/
pph2/; SIFT: sift.jcvi.org/; UMD-Predictor: http://umd-pre-
dictor.eu/analysis.php and Mutation taster: http://www.mu-
tationtaster.org/) were used to assess the deleteriousness of
missense mutations.
A three-dimensional model of human GMPPB was ob-
tained using a combination of threading and homology
modeling methods [20]. The quality of predicted models
was assessed using the Qmean server [21] and energy
minimization of protein models was carried out using the
3DRefine web server [22]. The effects of GMPPB missense
mutations on protein stability and the change in thermo-
dynamic folding stability (the difference in Gibbs free en-
ergy between wild-type and mutant, ΔΔG) were calculated
using FoldX [23], an algorithm that uses an empirical force
field to evaluate the effect of mutations on protein stability.
The calculated free energy differences (ΔΔG) [24] indicate
the change in structural stability, with negative values indi-
cating amino acid substitutions that tend to increase the
thermodynamic structural rigidity of the proteins, and posi-
tive values indicating variants that tend to destabilize pro-
teins. The RepairPDB function was applied to the GMPPB
wild-type structure before running the BuildModel function
of FoldX, and nine independent runs were carried out for
each mutation. The prediction error of FoldX is approxi-
mately 0.5 kcal/mol, therefore changes in that range are in-
significant. UCSF Chimera software (version 1.11) [25] was
used for molecular graphics and GraphPad Prism was used
for data analysis and curve fitting.
Western blotting (WB) was undertaken as described
[26] on a limited number of samples (P1, P2, P3, P6, and
P7), depending on material availability. Mouse monoclo-
nal antibodies used on blots were to β-dystroglycan
(NCL-b-DG, Leica Biosystems) and laminin α2 (MAb
1922, Chemicon). Western blots were visualized using
the Pierce Supersignal detection system according to the
manufacturer’s directions. The density of the myosin
heavy chain (MHC) band on the Coomassie blue stained,
post-blotted gel was a marker for protein loading.
Results
Thirteen patients (8 men and 5 women, age range at last
examination 20 months–74 years) from a cohort of 73
Italian α-DG cases showed two predictably pathogenic
mutations in GMPPB. The patients’ clinical data are
summarized in Table 1. Patient P6 has already been de-
scribed in detail elsewhere [15]. Patients 9 and 10 are
uncle and nephew; the remaining patients are unrelated.
Five patients (P1–P5) presented onset at birth or in
the first year of life, and three (P6, P7, P11) during child-
hood. The other five had adult onset of their muscle
weakness (> 18 years). All 13 patients, albeit to different
degrees, presented proximal weakness both of the shoul-
der and the pelvic girdle. Contractures and scoliosis
were part of the picture in 4/13 cases, and two patients
with congenital onset (P3 and P4) displayed arthrogrypo-
sis. Generalized or focal epilepsy (both tonic-clonic and
focal seizures with impaired awareness and oromastica-
tory automatisms) was seen in all the patients with con-
genital onset, and in one case with childhood onset (P6).
All the patients with congenital onset showed intellec-
tual disability and were unable to produce full sentences;
P1 has a diagnosis of autism spectrum disorder. Two pa-
tients with congenital onset (P2 and P4) showed bilateral
cataracts. One case (P1) displayed nystagmus and inward
strabismus, with reduction of lateral movement, and
upgaze palsy. Two of the LGMD patients (P6 and P7)
displayed exercise intolerance and four (P8, P11, P12,
P13) easy fatigability; anyway only P8 received pharma-
cological treatment showing a partial response to pyrido-
stigmine. No respiratory or cardiac involvement was
found in this cohort, except for slight heart conduction
impairment in three patients (one of whom [P6] carried
a diagnosis of Wolf–Parkinson–White syndrome).
The disease was usually progressive over time, how-
ever most of the patients who achieved ambulation were
still ambulant at the time of diagnosis.
Serum CK levels were increased (ranging from 316 to
38,650 UI/L); muscle biopsy showed features of a mus-
cular dystrophy with abnormal variation in fiber size, ne-
crosis and fibrosis, and in two cases (P5 and P6) it
highlighted a myolitic process. Immunohistochemistry
with the IIH6 antibody revealed variable degrees of
hypoglycosylation of α-dystroglycan. Electromyography
was normal in some cases, and otherwise showed mild
to moderate myopathic changes. Repetitive nerve stimu-
lation was performed in three LGMD patients (P6, P8
and P13), and only in P8 revealed findings consistent
with abnormal neuromuscular transmission in proximal
muscles. Brain MRI was available in 6 patients (P1-P6)
and showed features previously observed in published
GMPPB-mutated patients (Table 1). Muscle MRI was
available only in two patients (P1 and P6): the first one,
with a CMD phenotype, presented a prevalent involve-
ment of vastus lateralis at thigh level and minimal in-
volvement of soleus at the calves. The second patient
with a LGMD phenotype showed minimal involvement
Astrea et al. Orphanet Journal of Rare Diseases  (2018) 13:170 Page 3 of 9
Ta
b
le
1
C
lin
ic
al
fe
at
ur
es
in
13
pa
tie
nt
s
ha
rb
or
in
g
bi
-a
lle
lic
m
ut
at
io
ns
in
G
M
PP
B
C
as
e/
Se
x
P1
/M
P2
/M
P3
/M
P4
/F
P5
/M
P6
/F
P7
/M
P8
/M
P9
/M
a
P1
0/
M
a
P1
1/
F
P1
2/
F
P1
3/
M
M
ut
at
io
ns
p.
I2
19
T
p.
R2
87
Q
p.
T1
53
I
p.
Q
23
4*
p.
K3
1E
p.
G
17
4S
p.
T1
53
I
p.
P3
2L
p.
P3
2L
p.
R2
87
Q
p.
G
31
5S
p.
D
27
H
p.
S1
68
F
p.
Q
23
4*
p.
R2
43
W
p.
P3
2L
p.
D
27
H
p.
V3
30
I
p.
D
27
H
p.
V3
30
I
p.
R2
88
Q
p.
C
28
5Y
fs
X1
9
p.
G
22
0R
p.
R2
87
Q
p.
R2
87
Q
p.
V3
30
I
D
ia
gn
os
is
C
RB
M
EB
C
M
D
-M
R
C
RB
C
RB
LG
M
D
LG
M
D
LG
M
D
LG
M
D
LG
M
D
LG
M
D
LG
M
D
LG
M
D
O
ns
et
18
m
on
th
s
bi
rt
h
bi
rt
h
bi
rt
h
bi
rt
h
6
ye
ar
s
13
ye
ar
s
20
ye
ar
s
28
ye
ar
s
24
ye
ar
s
7
ye
ar
s
25
ye
ar
s
34
ye
ar
s
D
is
tr
ib
ut
io
n
of
w
ea
kn
es
s
A
xi
al
an
d
up
pe
r
gi
rd
le
Pr
ox
im
al
lo
w
er
gi
rd
le
ge
ne
ra
liz
ed
ge
ne
ra
liz
ed
ge
ne
ra
liz
ed
M
ild
up
pe
r
an
d
lo
w
er
lim
b
gi
rd
le
M
ild
pr
ox
im
al
M
ild
pr
ox
im
al
M
ild
up
pe
r
an
d
lo
w
er
lim
b
gi
rd
le
M
ild
up
pe
r
an
d
lo
w
er
lim
b
gi
rd
le
M
ild
pr
ox
im
al
M
ild
pr
ox
im
al
M
ild
pr
ox
im
al
M
ax
im
al
m
ot
or
ac
qu
is
iti
on
In
de
pe
nd
en
t
w
al
k
w
ith
w
id
en
in
g
ba
se
In
de
pe
nd
en
t
w
al
k
w
ith
fla
t
fo
ot
Si
tt
in
g
po
si
tio
n
no
ne
no
ne
Ru
n
w
ith
m
ild
cl
um
si
ne
ss
ru
n
ru
n
Ru
n
bu
t
lo
ss
of
am
bu
la
tio
n
at
58
ye
ar
s
ru
n
ru
n
ru
n
ru
n
In
te
lle
ct
ua
l
di
sa
bi
lit
y
+
(m
ild
)
A
SD
+
(m
ild
)
+
(m
ild
)
+
(s
ev
er
e)
+
(s
ev
er
e)
–
–
–
–
–
–
–
–
Ep
ile
ps
y
+
+
+
+
dr
ug
re
si
st
an
t
+
+
–
–
–
–
–
–
–
Br
ai
n
M
RI
fin
di
ng
s:
C
er
eb
el
la
r
hy
po
pl
as
ia
W
M
C
G
M
C
m
ild
- M
ic
ro
ce
ph
al
y
- + -
- - M
ic
ro
ce
ph
al
y
m
ild
- Po
ly
m
ic
ro
gy
ria
/
M
ic
ro
ce
ph
al
y
m
ild
- C
or
tic
al
hy
po
pl
as
ia
/
M
ic
ro
ce
ph
ay
- + -
N
ot
pe
rfo
rm
ed
N
ot
pe
rfo
rm
ed
N
ot
pe
rfo
rm
ed
N
ot
pe
rfo
rm
ed
N
ot
pe
rfo
rm
ed
N
ot
pe
rfo
rm
ed
N
ot
pe
rfo
rm
ed
O
ph
th
al
m
ol
og
ic
fin
di
ng
s
St
ra
bi
sm
us
N
ys
ta
gm
us
C
at
ar
ac
t
C
on
ge
ni
ta
l
ca
ta
ra
ct
–
C
on
ge
ni
ta
l
ca
ta
ra
ct
–
–
–
–
–
–
–
–
–
C
ar
di
or
es
pi
ra
to
ry
fin
di
ng
s
–
Re
sp
ira
to
ry
di
st
re
ss
at
bi
rt
h
Re
sp
ira
to
ry
di
st
re
ss
at
bi
rt
h
Re
sp
ira
to
ry
di
st
re
ss
at
bi
rt
h,
su
dd
en
he
ar
t
bl
oc
k
at
20
m
on
th
s
–
W
ol
ff-
Pa
rk
in
so
n-
W
hi
te
ty
pe
B
sy
nd
r.o
m
e
–
–
–
–
Sh
or
t
Q
T
in
te
rv
al
–
–
O
th
er
fe
at
ur
es
–
Fa
ci
al
di
m
or
ph
is
m
s
Fa
ci
al
di
m
or
ph
is
m
s,
fo
ot
de
fo
rm
iti
es
ky
ph
os
is
A
rt
hr
og
ry
po
si
s
Tu
be
Fe
ed
Ex
er
ci
se
in
to
le
ra
nc
e
m
yo
gl
ob
in
ur
ia
Ex
er
ci
se
in
to
le
ra
nc
e
Ea
sy
fa
tig
ab
ili
ty
–
–
Sc
ol
io
si
s
fa
tig
ab
ili
ty
Sc
ol
io
si
s
fa
tig
ab
ili
ty
M
ild
fa
tig
ab
ili
ty
A
bb
re
vi
at
io
ns
:M
m
en
,F
w
om
en
,W
M
C
w
hi
te
m
at
te
r
ch
an
ge
s,
G
M
C
gr
ey
m
at
te
r
ch
an
ge
s,
CR
B
co
ng
en
ita
lm
us
cu
la
r
dy
st
ro
ph
y
w
ith
ce
re
be
lla
r
in
vo
lv
em
en
t,
CM
D
-M
R
co
ng
en
ita
lm
us
cu
la
r
dy
st
ro
ph
y
w
ith
m
en
ta
l
re
ta
rd
at
io
n,
LG
M
D
lim
b
gi
rd
le
m
us
cu
la
r
dy
st
ro
ph
y;
+
pr
es
en
t;
−
ab
se
nt
;a
th
es
e
pa
tie
nt
s
ar
e
un
cl
e
an
d
ne
ph
ew
;A
SD
au
tis
m
sp
ec
tr
um
di
so
rd
er
;M
EB
,m
us
cl
e-
ey
e-
br
ai
n
di
se
as
e
*i
nd
ic
at
es
in
ge
ne
tic
s
th
e
pr
es
en
ce
of
a
ST
O
P
C
O
D
O
N
Astrea et al. Orphanet Journal of Rare Diseases  (2018) 13:170 Page 4 of 9
of adductor magnus, semimebranosus, semitendinosus and
sartorius muscles at thigh level, whereas revealed a mild
fatty streaking in soleus and peroneal muscles at calf level.
The 13 patients carried 15 different mutations (seven
were novel) in GMPPB, including 13 missense variants,
one nonsense, and one frameshift (Fig. 1; Table 2). The
mutations appear evenly distributed throughout the dif-
ferent domains/inter-domains of the protein and induce
distinct alterations in the conformation of the protein
(Additional file 1: Figure S1). The predicted ΔΔG values
of the different GMPPB mutations were found to range
from 5.7 to 13.7 kcal/mol (Fig. 2a), and showed the clas-
sical Gaussian distribution previously described for other
proteins [24]. The mean of the high destabilizing score
(μ = 2.1 kcal/mol, R = 0.96; Fig. 2b) suggested that most
GMPPB mutations affect the thermodynamic stability of
the protein. In particular, 33% of mutations were recog-
nized as stabilizing (ΔΔG < − 0.46 kcal/mol) and 54% as
destabilizing (ΔΔG > 0.46 kcal/mol) (Fig. 2c), while a
small percentage appeared to be neutral (− 0.46 <ΔΔG <
0.46 kcal/mol; Fig. 2a, c).
Finally, we investigated whether mutations with differ-
ent scores may have different effect on other proteins
known to be secondarily affected in GMPPB dystroglyca-
nopathy [26]. WB confirmed a mobility shift of
β-dystroglycan in all the patients analyzed and a variable
reduction of laminin α2, which was not correlated with
the nature of mutations in GMPPB (Fig. 3).
Discussion
This is the first Italian population study regarding
GMPPB-related dystroglycanopathy and encompassing
all the previously reported related clinical phenotypes.
Only 18% of the patients in our cohort (13/73) harbored
pathogenic mutations in GMPPB, and only five pre-
sented a CMD phenotype. This latter finding is in line
with data from the literature [11, 26–28], which indicate
that mutations in GMPPB are more common in rela-
tively milder forms of neuromuscular disorders.
No significant clinical findings seemed to emerge in
the CMD group, as the features found in these patients,
including intellectual disability, ophthalmic involvement,
epilepsy and microcephaly, are also typical of other dys-
troglycanopathies [11]. However, what our study adds to
this already broad clinical spectrum is the possible pres-
ence of arthrogryposis and congenital clubfoot, particu-
larly in patients with very severe, generalized involvement,
as well as nystagmus and upgaze palsy.
Intellectual disability was evident in all the congenital
forms, predominantly affecting the language domain.
Epilepsy appeared to be related to cognitive impairment
and not to the presence of MRI alterations. Autism
spectrum disorder emerged as a rare neurodevelopmen-
tal comorbidity. At this stage, we cannot totally exclude
that an additional variant in neurodevelopmental genes
can co-occur, at least in some patients, in a sort of
“double trouble” condition. Contrary to the findings of
others [14], none of our patients displayed movement
disorders such as chorea, whereas ataxia could be part
of the clinical picture in line with possible evidence of
cerebellar atrophy. On the basis of data from the litera-
ture and from our case studies, it can confidently be
asserted that mutations in GMPPB predominantly affect
the brain in CMD infants. Unless these patients’ clinical
Fig. 1 Morbidity map of GMPPB in Italian patients with α-dystroglycanopathy compared to mutations reported in literature. The scheme of the
GMPPB protein is illustrated and the mutations identified in this study depicted in bold (novel mutations are in red, published mutations are in black)
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and laboratory features are evaluated in a tertiary center
specializing in neuromuscular diseases, this might lead
to a suspicion of encephalopathy and prevent the condi-
tion from being diagnosed early.
The onset of motor manifestations in the LGMD
group occurred at different ages and, as previously re-
ported, the extent of weakness was unrelated to the tim-
ing of onset of the disease. On the other hand, features
such as intellectual disability or epilepsy can be the first
manifestations of the disease and are frequent in those
patients who have earliest (< 18 years) muscle involve-
ment. None of our LGMD patients displayed cognitive
impairment or brain MRI alterations.
The patients with the milder forms manifested easy fatig-
ability or myoglobinuria, or (P8) presented relatively asymp-
tomatic hyperCKemia with subtle weakness, evident only
on expert clinical examination. Few cases had overlapping
LGMD and CMS features, however we did not specifically
set out to identify patients with pathological neurophysio-
logical data, and abnormal neuromuscular transmission in
proximal muscles was detected in P8 only after establishing
the molecular diagnosis. Contrary to literature data, none
of our patients showed facial weakness or ptosis and cata-
racts were not invariably detected in our patients.
Muscle MRI did not reveal, in our cohort, a striking
pattern of muscle involvement maybe in consideration
of the different ages and phenotypes displayed by the
two patients analyzed (P1 and P6). However, as reported
previously [13, 26] we observed a prevalent involvement
of posterior compartment of the thigh with a relative at-
rophy of the anterior compartment, and a minor in-
volvement of the lower limb.
Through this work, we have expanded the array of
pathogenic variants associated with GMPPB, and shown
that these mutations are widely distributed within the
coding exons and located both in the C and in the
N-terminal domains (see Additional file 1: Figure S1). In
this sample at least, the clinical phenotype did not ap-
pear to be related to a specific mutation site within the
protein structure. Nonetheless, in an attempt to identify
possible genotype-phenotype correlations, we analyzed
the allelic frequency of the common variants identified
in our population and studied the effects of these muta-
tions on protein stability computing the changes in the
thermodynamic folding free energy (ΔΔG). Two muta-
tions (p.R287Q and p.D27H) were found to be common
in our study, having an allelic frequency of 15.4 and
11.5%, respectively, rates similar to those reported in the
Table 2 Genetic findings in patients with mutations in GMPPB
Mutation SIFT (score) Polyphen 2 score Protein domain Amino acid conservation Reference
P1 p.I219T
p.R287Q
Deleterious (0.04)
Tolerated (0.27)
Benign 0,267
Benign 0,117
N-TC domain
LbH
moderately conserved
weakly conserved
[28]
[11]
P2 p.T153I
p.Q234*
Tolerated (0.22)
na
Possibly damaging 0,812
na
N-TC domain
na
weakly conserved
weakly conserved
[14]
This work
P3 p.K31E
p.G174S
Deleterious (0.02)
Deleterious (0)
Probably damaging 0,992
Probably damaging 1,00
N-TC domain
N-TC domain
highly conserved
highly conserved
This work
This work
P4 p.T153I
p.P32L
Tolerated (0.22)
Deleterious (0)
Possibly damaging 0,812
Probably damaging 1,00
N-TC domain
N-TC domain
weakly conserved
highly conserved
[14]
[11]
P5 p.P32L
p.R287Q
Deleterious (0)
Tolerated (0.27)
Probably damaging 1,00
Benign 0,117
N-TC domain
LbH
highly conserved
weakly conserved
[11]
[11]
P6 p.G315S
p.D27H
Deleterious (0,01)
Deleterious (0,02)
Probably damaging 0,989
Benign 0,089
LbH
N-TC domain
highly conserved
weakly conserved
[15]
[11]
P7 p.S168F
p.Q234*
Deleterious (0,01)
na
Probably damaging 1,00
na
N-TC domain
na
highly conserved
weakly conserved
This work
This work
P8 p.R243W
p.P32L
Deleterious (0,02)
Deleterious (0)
Benign (0,006)
Probably damaging 1,00
na
N-TC domain
highly conserved
highly conserved
[26]
[11]
P9 p.D27H
p.V330I
Deleterious (0,02)
Deleterious (0)
Benign 0,089
Probably damaging (0,981)
N-TC domain
na
weakly conserved [11]
[27]
P10 p.D27H
p.V330I
Deleterious (0,02)
Deleterious (0)
Benign 0,089
Probably damaging (0,981)
N-TC domain
na
weakly conserved
highly conserved
[11]
[27]
P11 p.R288G
p.C285YfsX19
Deleterious (0.01)
na
Probably damaging (0.980) LbH
LbH
moderately conserved
weakly conserved
This work
This work
P12 p.G220R
p.R287Q
Deleterious (0)
Tolerated (0.27)
Probably damaging (0.999)
Benign 0,117
N-TC domain
LbH
highly conserved
weakly conserved
This work
[11]
P13 p.R287Q
p.V330I
Tolerated (0.27)
Damaging(0)
Benign 0,117
Probably damaging (0,981)
LbH
na
weakly conserved
highly conserved
[11]
[27]
Legend: na not applicable, N-TC domain N terminal catalytic domain, LbH Left-handed parallel beta-Helix domain. Novel mutations are in bold
*indicates in genetics the presence of a STOP CODON
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literature [27]. Conversely, p.V330I, found in 3/26 alleles
in our study, has only occasionally been reported else-
where. Interestingly, p.V330I appeared to be pseudo-
dominantly inherited in one family (P9 and P10,
Additional file 2: Figure S2). We cannot firmly establish
whether family members were distantly related and the
possibility of an independent inheritance of the p.D27H
mutation cannot be excluded.
Examining our data we observed that all the patients
carrying p.D27H (P6, P9, P10) showed a mild phenotype
Fig. 2 Energy changes of missense mutations in GMPPB. a Histogram of calculated free energy changes (ΔΔG) due to missense mutations in GMPPB.
Orange-, gray- and green-shaded bars indicate mutated residues falling in the N-terminal catalytic domain, inter-domains and C-terminal LbH domain,
respectively. b The ΔΔG distributions of GMPPB missense mutations. The ΔΔG values of mutations were presented in histograms, using 3 kcal/mol
bins (the single mutation with ΔΔG = 13.7 kcal/mol was classified into the > 10 kcal/mol bin) and the distribution was fitted to a Gaussian function.
c Histogram of the number of mutations (%) plotted against the predicted effect of mutations on GMPPB stability
Fig. 3 Western blot analysis of patients with mutations in the GMPPB gene. Consistent lower mobility shift of β-dystroglycan (β-DG) and variable
expression of laminin α2 (LAMA2) in skeletal muscle biopsies from five patients (P1, P2, P3, P6, and P7) with mutations in the GMPPB gene.
Myosin heavy chain (MHC) was used as measure of protein loading. CTRL, control muscle
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as previously described, and this is in keeping with this
mutation’s neutral effect on protein stability (Fig. 2a). The
reverse is true for p.D287Q whose ΔΔG value predicted a
stabilizing effect on the protein. Furthermore, p.R287Q, if
combined with the likely destabilizing effect of p. I219T or
p.P32L, might predict a severe phenotype (as in P1 or P5,
respectively), whereas its association with a neutral variant
(e.g. p.G220R in P11 or p.V330I, as in P12) might suggest
a less aggressive phenotype. Similar considerations prob-
ably apply in the case of association of the most common
variant, p.D27H (often seen in LGMD-CMS patients),
with the more severe p.P32L mutation.
Consistent with previous findings [26], we observed
that patients with GMPPB dystroglycanopathy share the
unique biochemical feature of a change in electrophor-
etic mobility of β-dystroglycan. As there was not appar-
ent correlation between the predicted stability of
mutated GMPPB and residual expression of glycosylated
α-dystroglycan or secondary reduction of laminin α2
(Fig. 3 and not shown), the finding that β-dystroglycan is
equally affected in all patients regardless of the predicted
stability of the mutations suggests that the overall
retained function of GMPPB may be key to the variabil-
ity in patients’ phenotype.
Conclusions
To summarize, this study describes a sample of 13 Ital-
ian patients carrying a total of 15 different mutations in
GMPPB, representing 18% of our study cohort of α-DG
patients. Accordingly, GMPPB seems to be one of the
more frequent “second generation” α-DG-related genes
discovered in the NGS era. Our findings, combined with
literature data, show that there are at least three forms
of GMPPB-related myopathy: i) CMD, ii) early onset
LGMD, and iii) adult onset LGMD, often with evidence
of neuromuscular junction involvement. Less severe
phenotypes are also observed, such as exercise intoler-
ance and myoglobinuria (in P6) or asymptomatic
hyperCKemia (P8). In the absence of information on re-
sidual enzyme activity in tissues, combining clinical find-
ings with bioinformatic data on variant stability might
allow objective assessment of disease severity.
Additional files
Additional file 1: Figure S1. (A) Effects of missense mutations on the
structure of GMPPB. The images show the close-up of the different mutation
sites with the predicted consequences of the amino acid replacement.
Wild-type protein is shown in gray and mutated proteins in magenta. The
side chain of wild-type and mutated residues are shown as sticks. Mutated
residues located in the N-terminal catalytic domain, inter-domains and C-
terminal LbH domain are shown on orange, gray and green backgrounds,
respectively. (B) Distribution of missense mutations between the domains
and inter-domains of the GMPPB protein reported as number of mutations
per amino acid. Orange bar, N-terminal catalytic domain; gray bar,
inter-domains; green bar, C-terminal LbH domain. (PDF 8212 kb)
Additional file 2: Figure S2. Pedigree of the family showing pseudo-
dominant inheritance in GMPPB disease. Two patients (uncle and nephew,
P9 and P10, respectively) showed onset in early adulthood and similar
muscular impairments associated with biallelic mutations (p:Asp27His and
p.Val330Ile) in GMPPB. Circles are females and squares are males. Slashed
symbols indicate deceased individuals. Numbers in symbols indicate number
of siblings. (PDF 7 kb)
Abbreviations
CMD: Congenital muscular dystrophy; CMS: Congenital myasthenic syndrome;
GMPPB: Guanosine-diphosphate-mannose (GDP-mannose) dyrophosphorylase
B gene; LGMD: Limb-girdle muscular dystrophy; MRI: Magnetic resonance
imaging; NGS: Next-generation sequencing; WWS: Walker-Warburg syndrome;
α-DG: alpha-dystroglycanopathy
Acknowledgements
The authors thank Catherine J. Wrenn, who provided expert editorial
assistance.
#The Italian Network on Congenital Muscular Dystrophies comprises the
following researchers:
Angela Berardinelli1, Giacomo Comi2, Maria Alice Donati3, Maria Teresa Dotti4,
Marina Grandis5, Francesca Magri2, Maria A. Maioli6, Alessandro Malandrini4,
Francesco Mari3, Roberto Massa7, Luciano Merlini8, Maurizio Moggio2, Lucia
O. Morandi9, Olimpia Musumeci10, Marika Pane11, Antonella Pini8, Elena
Pegoraro12, Elena M. Pennisi13, Lorenzo Peverelli2, Giulia Ricci14, Carmelo
Rodolico10, Lucia Ruggiero15, Michele Sacchini3, Lucio Santoro15, Gabriele
Siciliano14, Alessandro Simonati16, Paola Tonin16, Antonio Toscano10.
1UO Neuropsichiatria Infantile, C. Mondino National Neurological Institute,
Pavia, 2UO Neurology, Maggiore Hospital, and Neuromuscular and Rare
Diseases Unit, Dino Ferrari Center, Milan, 3Meyer Children Hospital, Florence,
4Neurology, University of Siena, Siena, 5Department of Neuroscience, Rehabilitation,
Ophthalmology, Genetics, University of Genoa, Genoa, 6Neurophysiopathology
Multiple Sclerosis Center Hospital Binaghi, Cagliari, 7UOC Neurology, Policlinico
Tor Vergata, Rome, 8University of Bologna, Bologna, 9Muscle Cell Biology Lab,
Neuromuscular Diseases and Neuroimmunology Unit, Fondazione IRCCS C.
Besta, Milan, 10UOC Neurology and Neuromuscular Diseases, AOU Policlinico G.
Martino, Messina, 11U.O. Neuropsichiatria Infantile, A. Gemelli Hospital,
Rome,12Department of Neurology, Hospital of Padua, Padua, 13UOC Neurology,
San Filippo Neri, Rome, 14UO Neurology, AOUP, Pisa, 15UO Neurology, Policlinico
Federico II, Naples, 16UOC Neurology, Borgo Roma Hospital, Verona.
Funding
This work was partially funded by Regione Toscana FAS SALUTE 2014 (CUP
4042.16092014.066000060 to FMS) and Telethon Foundation grants
GUP13004 to AD, GA, CB, EM and LP). FMu and IZ gratefully acknowledge the
European Community’s Seventh Framework Programme (FP7/2007–2013)
funded grant “Integrated European –omics research project for diagnosis and
therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)”
(grant agreement n° 2012–305121); the Muscular Dystrophy UK Grant on Gene
Identification to FMu. FMu is supported by the National Institute for Health
Research Biomedical Research Centre at Great Ormond Street Hospital for
Children NHS Foundation Trust and University College London; the views
expressed in this article are those of the author(s) and not necessarily those of
the NHS, the NIHR or the Department of Health.. The support of the Muscular
Dystrophy UK to the Dubowitz Neuromuscular Centre and of the MRC
Neuromuscular Centre Biobank is also gratefully acknowledged.
Availability of data and materials
The dataset supporting the conclusions of this article are included within the
article and its additional files.
Authors’ contributions
GA, CF and AD coordinated the collection and elaboration of data. GA and
AR drafted the manuscript. CD, RT, FM, FeM, IP, MP, FF, IZ, and WS performed
and interpreted the molecular analysis. AR: performed functional in silico
studies on selected mutations. RiB and CF reviewed Western blotting in muscle
biopsies. CF and AR reviewed the muscle biopsies. CA, CGA, RB, CB, MF, RG, LM,
MM, EP, LP, PS and CT, provided patients data. VN and MS reviewed the genetic
results. FMS, EB, CB, EM, FMu conceived the study and helped in drafting the
manuscript. All authors read and approved the final manuscript.
Astrea et al. Orphanet Journal of Rare Diseases  (2018) 13:170 Page 8 of 9
Ethics approval and consent to participate
This study was approved by the Regione Toscana Pediatric Ethic Review Board.
Consent for publication
Written informed consent was obtained from all subjects or their legal guardians,
with explicit consent for future use for research purposes. Signed consent form
are available at patients referring centers.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Developmental Neuroscience and Molecular Medicine
Neuromuscular Unit and Child Neurology, IRCCS Fondazione Stella Maris, Via
dei Giacinti 2, 56018 Pisa, Italy. 2Neuropathology Unit, Institute of
Experimental Neurology and Division of Neuroscience, IRCCS San Raffaele
Scientific Institute, Milan, Italy. 3Fondazione San Camillo Hospital IRCCS, Lido
Venice, Italy. 4Department of Neuroimmunology and Neuromuscular
Disorders, Neurological Institute “C. Besta” IRCCS Foundation, Milan, Italy.
5Rare Diseases Advisory Group Service for Neuromuscular Diseases, Muscle
Immunoanalysis Unit, Dental Hospital, and The John Walton Muscular
Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases Institute
of Genetic Medicine, University of Newcastle, Newcastle upon Tyne, UK.
6Department of Clinical and Experimental Medicine, University of Pisa, Pisa,
Italy. 7Department of Medical, Surgical and Neurosciences, University of
Siena, Siena, Italy. 8Unit of Neuromuscular and Neurodegenerative Disorders,
Department of Neurosciences, Bambino Gesù Children’s Hospital, Rome, Italy.
9Center of Myology and Neurodegenerative Disorders, G. Gaslini Institute,
Genoa, Italy. 10Neurological Science Department and Venetian Institute of
Molecular Medicine, University of Padua, Padua, Italy. 11Pediatric Neurology
and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation,
Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, “G.
Gaslini” Institute, Genoa, Italy. 12Pediatric Neurology Unit and Laboratories,
Children’s Hospital A. Meyer-University of Florence, Florence, Italy. 13Pediatric
Neurology Unit, Department of Women’s and Children’s Health, Università
Cattolica del Sacro Cuore, Rome, Italy. 14Cardiomyology and Genetic Section,
Department of Internal and Experimental Medicine, University of Campania
“Luigi Vanvitelli”, Naples, Italy. 15Department of Translational Medicine,
Federico II University, Naples, Italy. 16Telethon Institute of Genetics and
Medicine, Pozzuoli, Naples, Italy. 17Sequentia Biotech SL, Barcelona, Spain.
18Dipartimento di Biochimica, Biofisica e Patologia Generale, Università degli
Studi della Campania “Luigi Vanvitelli”, Naples, Italy. 19Folkhälsan Institute of
Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland.
20Department of Neurological and Psychiatric Sciences, University of Padua,
Padua, Italy. 21Dubowitz Neuromuscular Centre (F. Muntoni), UCL Great
Ormond Street Institute of Child Health, London, UK. 22NIHR Great Ormond
Street Hospital Biomedical Research Centre, 30 Guilford Street, London
WC1N 1EH, UK.
Received: 8 March 2018 Accepted: 29 June 2018
References
1. Muntoni F, Brockington M, Blake DJ, Torelli S, Brown SC. Defective glycosylation
in muscular dystrophy. Lancet. 2002;360:1419–21.
2. Toda T, Kobayashi K, Takeda S, Sasaki J, Kurahashi H, Kano H, et al. Fukuyama-
type congenital muscular dystrophy (FCMD) and alphadystroglycanopathy.
Congenit Anom (Kyoto). 2003;43:97–104.
3. Brockington M, Muntoni F. The modulation of skeletal muscle glycosylation
as a potential therapeutic intervention in muscular dystrophies. Acta Myol.
2005;24:217–21.
4. Mercuri E, Topaloglu H, Brockington M, Berardinelli A, Pichiecchio A,
Santorelli F, et al. Spectrum of brain changes in patients with congenital
muscular dystrophy and FKRP gene mutations. Arch Neurol. 2006;63:251–7.
5. van Reeuwijk J, Brunner HG, van Bokhoven H. Glyc-O-genetics of Walker-
Warburg syndrome. Clin Genet. 2005;67:281–9.
6. Brockington M, Yuva Y, Prandini P, Brown SC, Torelli S, Benson MA, et al.
Mutations in the fukutin-related protein gene (FKRP) identify limb girdle
muscular dystrophy 2I as a milder allelic variant of congenital muscular
dystrophy MDC1C. Hum Mol Genet. 2001;10:2851–9.
7. Graziano A, Bianco F, D'Amico A, Moroni I, Messina S, Bruno C, et al.
Prevalence of congenital muscular dystrophy in Italy: a population
study. Neurology. 2015;84:904–11.
8. Sframeli M, Sarkozy A, Bertoli M, Astrea G, Hudson J, Scoto M, et al. Congenital
muscular dystrophies in the UK population: cinical and molecular spectrum of
a large cohort diagnosed over a 12-year period. Neuromuscul Disord. 2017;27:
793–803.
9. Bönnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, et
al. Diagnostic approach to the congenital muscular dystrophies. Neuromuscul
Disord. 2014;24:289–311.
10. O'Grady GL, Lek M, Lamande SR, Waddell L, Oates EC, Punetha J, et al.
Diagnosis and etiology of congenital muscular dystrophy: we are halfway
there. Ann Neurol. 2016;80:101–11.
11. Carss KJ, Stevens E, Foley AR, Cirak S, Riemersma M, Torelli S, et al. Mutations in
GDP-mannose pyrophosphorylase B cause congenital and limb-girdle
muscular dystrophies associated with hypoglycosylation of α-dystroglycan. Am
J Hum Genet. 2013;93:29–41.
12. Belaya K, Rodríguez Cruz PM, Liu WW, Maxwell S, McGowan S, Farrugia ME, et al.
Mutations in GMPPB cause congenital myasthenic syndrome and bridge
myasthenic disorders with dystroglycanopathies. Brain. 2015;138(Pt 9):2493–504.
13. Oestergaard ST, Stojkovic T, Dahlqvist JR, Bouchet-Seraphin C, Nectoux J,
Leturcq F, et al. Muscle involvement in limb-girdle muscular dystrophy with
GMPPB deficiency (LGMD2T). Neurol Genet. 2016;2:e112.
14. Cabrera-Serrano M, Ghaoui R, Ravenscroft G, Johnsen RD, Davis MR, Corbett A,
et al. Expanding the phenotype of GMPPB mutations. Brain. 2015;138:836–44.
15. Panicucci C, Fiorillo C, Moro F, Astrea G, Brisca G, Trucco F, et al. Mutations
in GMPPB presenting with pseudometabolic myopathy. JIMD Rep. 2017;
https://doi.org/10.1007/8904_2017_25.
16. Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381:845–60.
17. Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, et al.
Refining genotype phenotype correlations in muscular dystrophies with
defective glycosylation of dystroglycan. Brain. 2007;130:2725–35.
18. Astrea G, Pezzini I, Picillo E, Pasquariello R, Moro F, Ergoli M, et al. TMEM5-
associated dystroglycanopathy presenting with CMD and mild limb-girdle
muscle involvement. Neuromuscul Disord. 2016;26:459–61.
19. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al.
Working Group of the American College of medical genetics and genomics
laboratory quality assurance Commitee. ACMG clinical laboratory standards
for next-generation sequencing. Genet Med. 2013;15:733–47.
20. Fiorillo C, Moro F, Yi J, Weil S, Brisca G, Astrea G, et al. Novel dynein DYNC1H1
neck and motor domain mutations link distal spinal muscular atrophy and
abnormal cortical development. Hum Mutat. 2014;35:298–302.
21. Benkert P, Künzli M, Schwede T. QMEAN server for protein model quality
estimation. Nucleic Acids Res. 2009;37:W510–4.
22. Bhattacharya D, Nowotny J, Cao R, Cheng J. 3Drefine: an interactive web
server for efficient protein structure refinement. Nucleic Acids Res. 2016;44:
W406–9.
23. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins
and protein complexes: a study of more than 1000 mutations. J Mol Biol. 2002;
320:369–87.
24. Tokuriki N, Stricher F, Schymkowitz J, Serrano L, Tawfik DS. The stability
effects of protein mutations appear to be universally distributed. J Mol
Biol. 2007;369:1318–32.
25. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC,
et al. UCSF chimera–a visualization system for exploratory research and
analysis. J Comput Chem. 2004;25:1605–12.
26. Sarkozy A, Torelli S, Mein R, Henderson M, Phadke R, Feng L, et al. Mobility
shift of beta-dystroglycan as a marker of GMPPB gene-related muscular
dystrophy. J Neurol Neurosurg Psychiatry. 2018; https://doi.org/10.1136/
jnnp-2017-316956.
27. Jensen BS, Willer T, Saade DN, Cox MO, Mozaffar T, Scavina M, et al. GMPPB-
associated dystroglycanopathy: emerging common variants with phenotype
correlation. Hum Mutat. 2015;36:1159–63.
28. Raphael AR, Couthouis J, Sakamuri S, Siskind C, Vogel H, Day JW, et al.
Congenital muscular dystrophy and generalized epilepsy caused by
GMPPB mutations. Brain Res. 2014;1575:66–71.
Astrea et al. Orphanet Journal of Rare Diseases  (2018) 13:170 Page 9 of 9
